iBio advances IBIO-600 into Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing
IBIO•Phase 1 trial advances after single-ascending-dose dosing
iBio advanced IBIO-600 into the Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing.
- iBio initiated a Phase 1 trial of IBIO-600 in fiscal 2026, moving the company into clinical-stage development.
- Single-ascending-dose dosing reached 31 of 32 planned participants; no safety issues blocked dose escalation.
- Multiple-ascending-dose escalation is next, positioning the program for broader evaluation as a muscle-preserving complement to GLP-1 therapies.
- Preclinical results for IBIO-610 were already presented, supporting potential fat-selective weight loss and reduced weight regain following GLP-1 discontinuation.
